Literature DB >> 27288333

Segmented ART - The new era in ART?

Kemal Ozgur1, Peter Humaidan2, Kevin Coetzee3.   

Abstract

Currently up to 4% of infants born in developing countries are conceived through assisted reproductive technology (ART). Even though most of these conceptions occur and progress without complications, ART procedures and processes may increase iatrogenesis through complications in - and after conception. We herein review and discuss the clinically and scientific implications and evidence of iatrogenesis, and show how the evolution in ART technologies and procedures has led to the current presumption that frozen embryo transfer might be a more optimal strategy than fresh embryo transfer, in terms of not only reproduction, but also of maternal and fetal outcomes. There is increasing scientific evidence to support the notion that controlled ovarian stimulation could induce significant changes to the endocrine profile of a reproductive cycle, especially to the reproductively important early luteal phase. These changes may not only have a negative effect on implantation and early placentation, but also on the mother, the fetus, and the infant. The overt consequences of controlled ovarian stimulation include ovarian hyperstimulation syndrome, reduced embryo implantation, increased ectopic pregnancy, and altered placentation and fetal growth. The cumulative scientific evidence from this review suggests that GnRHa trigger in segmented ART might constitute the future routine treatment regimen for IVF patients, providing a safe, effective, and patient friendly treatment.
Copyright © 2016 Society for Biology of Reproduction & the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  ART; GnRHa-trigger; Iatrogenesis; Perinatal; Segmented-ART

Mesh:

Year:  2016        PMID: 27288333     DOI: 10.1016/j.repbio.2016.04.001

Source DB:  PubMed          Journal:  Reprod Biol        ISSN: 1642-431X            Impact factor:   2.376


  6 in total

1.  Mosaic embryo transfer after oocyte in vitro maturation in combination with non-invasive prenatal testing (NIPT)-first report of a euploid live birth.

Authors:  Naomi Inoue; Rosmary Lopez; Andrea Delgado; Denisse Nuñez; Jimmy Portella; Luis Noriega-Hoces; Luis Guzmán
Journal:  J Assist Reprod Genet       Date:  2017-06-24       Impact factor: 3.412

2.  Frozen embryo transfer can be performed in the cycle immediately following the freeze-all cycle.

Authors:  Kemal Ozgur; Hasan Bulut; Murat Berkkanoglu; Peter Humaidan; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2017-09-22       Impact factor: 3.412

3.  Single best euploid versus single best unknown-ploidy blastocyst frozen embryo transfers: a randomized controlled trial.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Gonul Didem Akay Yoruk; Nevrah Nal Candurmaz; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2019-01-07       Impact factor: 3.412

4.  Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population.

Authors:  Kemal Ozgur; Hasan Bulut; Murat Berkkanoglu; Levent Donmez; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2019-02-21       Impact factor: 3.412

Review 5.  GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis.

Authors:  Thor Haahr; Matheus Roque; Sandro C Esteves; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-07       Impact factor: 5.555

6.  Cumulus cells surrounding oocytes with high developmental competence exhibit down-regulation of phosphoinositol 1,3 kinase/protein kinase B (PI3K/AKT) signalling genes involved in proliferation and survival.

Authors:  P G Artini; C Tatone; S Sperduti; M D'Aurora; S Franchi; G Di Emidio; R Ciriminna; M Vento; C Di Pietro; L Stuppia; V Gatta
Journal:  Hum Reprod       Date:  2017-12-01       Impact factor: 6.918

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.